Edesa Biotech, Inc. Common Shares
EDSAEdesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases. The company specializes in leveraging its proprietary microscopic antibody technology to create therapies that address unmet medical needs. Edesa's research primarily targets conditions such as allergic and autoimmune diseases, aiming to advance novel therapeutic options in these areas.
Company News
The ARDS market is projected to grow at a 3.8% CAGR through 2036, valued at USD 1.7 billion in 2025 across seven major markets. Growth is driven by rising ARDS incidence, advancements in critical care management, and the entry of emerging therapies including MultiStem, ExoFlo, ThyrOxy, and Gelsolin. Currently, no FDA-approved therapies specifical...
Over 18 pharmaceutical companies are developing targeted therapies for vitiligo, with promising pipeline drugs showing potential to transform treatment options beyond conventional approaches like corticosteroids and phototherapy.
Dr. Pardeep Nijhawan and Velan Capital have updated their beneficial ownership of securities in Edesa Biotech, Inc. Dr. Nijhawan acquired 100 Series B-1 Convertible Preferred Shares, while Velan Capital acquired 568 Series B-1 Convertible Preferred Shares, both for investment purposes.
Dr. Pardeep Nijhawan, the CEO of Edesa Biotech, Inc., has acquired beneficial ownership of more than 2% of the company's common shares through a series of transactions and the granting of restricted share units.
Shares of ReShape Lifesciences Inc. (NASDAQ: RSLS) rose sharply in pre-market trading after the company said it received FDA PMA supplement approval for its next-generation Lap-Band 2.0 FLEX. ReShape Lifesciences shares jumped 44.6% to $0.3630 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers RiskOn Interna...
